Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 7/20 | 0.38 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.37 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 2/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.35 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.35 |
| ▸ | TPX2 | Q9ULW0 | 1/20 | 0.35 |
| ▸ | AKT1 | P31749 | 1/20 | 0.34 |
| ▸ | AKT2 | P31751 | 1/20 | 0.34 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10594663 | 0.77 | NUDT1 (0.41) | NUDT1JAK2KDM4EALDH1A1JAK1 | |
| SCHEMBL3306356 | 0.77 | NUDT1 (0.57) | TNK2NUDT1KDM4EALDH1A1JAK1 | |
| SCHEMBL25646677 | 0.76 | LRRK2 (0.40) | NUDT1LRRK2JAK1MTORPDE10A | |
| SCHEMBL3599442 | 0.75 | NUDT1 (0.63) | CHEK1NUDT1JAK1AKT1AKT2 | |
| SCHEMBL10594458 | 0.75 | KDM4E (0.58) | NUDT1KDM4EALDH1A1SMN1; SMN2GAA | |
| SCHEMBL2256835 | 0.75 | POLB (0.42) | NUDT1KDM4EALDH1A1JAK1NPC1 | |
| SCHEMBL3584146 | 0.74 | JAK1 (0.60) | JAK2KDM4EALDH1A1JAK1SMN1; SMN2 | |
| SCHEMBL3297508 | 0.74 | NUDT1 (0.39) | TNK2NUDT1JAK2KDM4EALDH1A1 | |
| SCHEMBL10856202 | 0.72 | NUDT1 (0.38) | NUDT1JAK2KDM4EALDH1A1JAK1 | |
| SCHEMBL10594383 | 0.72 | NUDT1 (0.48) | NUDT1KDM4EALDH1A1JAK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022119-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | INCYTE CORPORATION | 2026-01-22 | — | — | US | disclosed |
| US-12466828-B2 | Bicyclic amines as CDK2 inhibitors | INCYTE CORPORATION (US) | 2025-11-11 | — | — | US | disclosed |
| US-20240174664-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | INCYTE CORPORATION | 2024-05-30 | — | — | US | disclosed |
| EP-3290418-B1 | JANUS KINASE (JAK) INHIBITORS | WUXI FORTUNE PHARMACEUTICAL CO LTD (CN) | 2019-05-15 | — | — | EP | disclosed |
| US-10174036-B2 | Substituted pyrazoles as JAK inhibitors | Wuxi Fortune Pharmaceutical Co., Ltd (CN) | 2019-01-08 | — | — | US | disclosed |
| US-10174036-B2 | Substituted pyrazoles as JAK inhibitors | Wuxi Fortune Pharmaceutical Co., Ltd (CN) | 2019-01-08 | — | — | US | disclosed |
| US-20180179209-A1 | JAK INHIBITORS | Wuxi Fortune Pharmaceutical Co., Ltd (CN) | 2018-06-28 | — | — | US | disclosed |
| US-20180179209-A1 | JAK INHIBITORS | Wuxi Fortune Pharmaceutical Co., Ltd (CN) | 2018-06-28 | — | — | US | disclosed |
| US-20180179209-A1 | JAK INHIBITORS | Wuxi Fortune Pharmaceutical Co., Ltd (CN) | 2018-06-28 | — | — | US | disclosed |
| EP-3290418-A1 | JAK INHIBITORS | Wuxi Fortune Pharmaceutical Co., Ltd (CN) | 2018-03-07 | — | — | EP | disclosed |
| WO-2016173484-A1 | JAK INHIBITORS | 南京明德新药研发股份有限公司 | 2016-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10174036-B2 | Substituted pyrazoles as JAK inhibitors | JAK1, JAK2, JAK3 | CHEK1 405/4885TNK2 844/4885NUDT1 2706/4885 |
| US-20260022119-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | CCNA1, CDK1, CCNE1 | CHEK1 211/4885TNK2 309/4885NUDT1 1340/4885 |
| US-20180179209-A1 | JAK INHIBITORS | JAK2, JAK1, JAK3 | CHEK1 448/4885TNK2 628/4885NUDT1 3577/4885 |
| US-20240174664-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | CDK2, CDK1, CCNI | CHEK1 64/4885TNK2 96/4885NUDT1 715/4885 |
| US-12466828-B2 | Bicyclic amines as CDK2 inhibitors | CDK2, CDK1, CCNI | CHEK1 64/4885TNK2 96/4885NUDT1 715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.